Effectiveness of neoadjuvant chemotherapy with lenvatinib plus pembrolizumab in advanced endometrial cancer: a case report
Lenvatinib plus pembrolizumab may represent a feasible neoadjuvant option for achieving tumor regression and enabling surgical resection with a pathological complete response in advanced endometrial cancer.
Authors
- Haruya Saji
- Tomomi Yokozawa
- Katsuyuki Konnai (ORCID: https://orcid.org/0000-0002-2606-2950)
- Chiaki Yoshikawa (ORCID: https://orcid.org/0000-0002-6589-387X)
- Tsuguto Notomi
- Hiroyuki Fujiwara
Institutions
- Jichi Medical University (JP)
- Kanagawa Prefectural Hospital Organization (JP)
- Nippon Medical School (JP)
Publication Details
- Journal
- Journal of Medical Case Reports
- Published
- 2026-03-03
- DOI
- https://doi.org/10.1186/s13256-026-05920-4
- Primary Topic
- Endometrial and Cervical Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00